Brentuximab vedotin, an antibody–drug conjugate, in patients with CD30‐positive haematologic malignancies and hepatic or renal impairment

AIMS: Brentuximab vedotin, an antibody–drug conjugate (ADC), selectively delivers the microtubule‐disrupting agent monomethyl auristatin E (MMAE) into CD30‐expressing cells. The pharmacokinetics of brentuximab vedotin have been characterized in patients with CD30‐positive haematologic malignancies....

Full description

Saved in:
Bibliographic Details
Published in:Br J Clin Pharmacol
Main Authors: Zhao, Baiteng, Chen, Robert, O'Connor, Owen A., Gopal, Ajay K., Ramchandren, Radhakrishnan, Goy, Andre, Matous, Jeffrey V., Fasanmade, Adedigbo A., Manley, Thomas J., Han, Tae H.
Format: Artigo
Language:Inglês
Published: John Wiley and Sons Inc. 2016
Subjects:
Clinical Trials
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5089583/
https://ncbi.nlm.nih.gov/pubmed/27115790
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.12988
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items